Henry C. Tseng

Henry C. Tseng

Auto-generated profile, based on publicly available information

Henry C. Tseng

Duke Eye Center, Duke University Medical Center, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2015 in Bone Research
Verified
Journal Article
Open access
DLDong Joon Lee
Dong Joon Lee
HTHenry C Tseng
Henry C Tseng
SWSing-Wai Wong
Sing-Wai Wong
ZWZhengyan Wang
Zhengyan Wang
MDMeng Deng
Meng Deng
CKChing-Chang Ko
Ching-Chang Ko
Bone Research, Published online: 7 July 2015; | doi:10.1038/boneres.2015.20

13 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JAJoshua Ames
Joshua Ames
TYTejabhiram Yadavalli
Tejabhiram Yadavalli
RSRahul Suryawanshi
Rahul Suryawanshi
JHJames Hopkins
James Hopkins
AAAlexander Agelidis
Alexander Agelidis
Deepak ShuklaDeepak Shukla
Deepak Shukla
Fast-replicating neurotropic herpesviruses exemplified by herpes simplex virus-1 (HSV-1) naturally infect the central nervous system (CNS). However, most individuals intrinsically suppress the virus during a primary infection and preclude it from significantly damaging the CNS. Optineurin (OPTN) is a conserved autophagy receptor with little understanding of its role in neurotropic viral infections. We show that OPTN selectively targets HSV-1 tegument protein, VP16, and the fusion glycoprotein, gB, to degradation by autophagy. OPTN-deficient mice challenged with HSV-1 show significant cognitive decline and susceptibility to lethal CNS infection. OPTN deficiency unveils severe consequences for recruitment of adaptive immunity and suppression of neuronal necroptosis. Ocular HSV-1 infection is lethal without OPTN and is rescued using a necroptosis inhibitor. These results place OPTN at the crux of neuronal survival from potentially lethal CNS viral infections.

1 June 2015 in Neurobiology of Aging
Verified
Journal Article
Closed access
HTHenry C. Tseng
Henry C. Tseng
TRThorfinn T. Riday
Thorfinn T. Riday
CMCelia McKee
Celia McKee
CBCatherine E. Braine
Catherine E. Braine
HBHoward Bomze
Howard Bomze
MEMichael D. Ehlers
Michael D. Ehlers

25 September 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NMNisha Mukherjee
Nisha Mukherjee
SMShan McBurney-Lin
Shan McBurney-Lin
AKAnthony Kuo
Anthony Kuo
RBRichard Bedlack
Richard Bedlack
HTHenry Tseng
Henry Tseng
Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease that primarily affects motor neurons. Recently, three causative genes have been implicated in both ALS and glaucoma. However, it is still uncertain whether patients with ALS have neurodegeneration in their retinas. If so, retinal thickness measurements might be a useful biomarker for ALS progression. Previous work in this area has been inconclusive, as it has not taken into account the effect of ophthalmic diseases on retinal thinning. To determine whether there are differences in retinal neurons in ALS patients utilizing spectral-domain optical coherence tomography (SD-OCT). We tested the hypothesis that ALS patients exhibit retinal neurodegeneration that is not associated with ophthalmic diseases. Observational, comparative, cross-sectional study performed on patients recruited from the Duke University Medical Center ALS clinic. Patients underwent a comprehensive ophthalmologic examination to rule out ocular pathology. 21 patients met inclusion criteria. Two eyes with ocular pathology were excluded, leading to a total of 40 eyes of 21 patients included in the study. Retinal neurodegeneration was assessed by retinal nerve fiber layer (RNFL) thickness measurement using SD-OCT (Spectralis; Heidelberg Engineering). ALS disease severity, determined through the ALS Functional Rating Scale (ALSFRS-R); mean and six sector RNFL thickness values compared to age-adjusted values in the normative database provided by Heidelberg Engineering; RNFL thickness correlation with ALSFRS-R, ALSFRS-R progression rate, forced vital capacity (FVC), and visual acuity. ALSFRS-R mean score was 30+/-10. Mean RNFL thickness in ALS patients was 88.95 +/- 10.8 microns, significantly thinner than values in the normative database (95.81 +/- 0.8). These RNFL thickness values did not demonstrate correlation to ALSFRS-R score, ALSFRS-R progression rate, FVC, intraocular pressure, or visual acuity. Using SD-OCT, our study shows that ALS patients without ocular pathology exhibit thinned retinal layers. Future studies are warranted to clarify the clinical relationship between retinal thinning and motor neuron loss in ALS.

1 June 2005 in Neurobiology of Disease
Verified
Journal Article
Closed access
HTHenry C. Tseng
Henry C. Tseng
MDMarc A. Dichter
Marc A. Dichter

2 May 2014 in BMJ Open
Verified
Journal Article
Open access
KMKelly W Muir
Kelly W Muir
ALAnnie Lim
Annie Lim
SSSandra Stinnett
Sandra Stinnett
AKAnthony Kuo
Anthony Kuo
HTHenry Tseng
Henry Tseng
MWMolly M Walsh
Molly M Walsh
Objectives: The purpose of this study was to identify risk factors for exposure of glaucoma drainage devices (GDD). Setting: This retrospective, observational study was conducted in the eye clinic of an academic medical centre. Participants: Participants included 1073 consecutive adults who underwent GDD surgery between 1 January 2005 and 1 January 2011. Participants were included if chart review indicated GDD surgery during the study period and excluded if at least 12 months of clinical follow-up was not available in the medical record. Primary outcome measure: The primary outcome measure was exposure of the GDD occurring at least 1 month after implant surgery. The characteristics of participants who experienced exposure of the implant were compared to the characteristics of participants who did not experience exposure. Results: Of the 1073 participants having undergone GDD surgery, 67 experienced exposure of the device. Neither the type of GDD, type of patch graft (eye bank sclera, Tutoplast sclera and Tutoplast pericardium), surgeon, location of GDD, number of GDD previously implanted into the eye, nor history of diabetes or uveitis were associated with likelihood of exposure. Women were more likely than men to experience exposure of the GDD (OR 2.004 (95% CI1.170 to 3.431)) in both univariable (p=0.011) and multivariable (p=0.013) analyses. In survival analysis, exposure of the GDD occurred earlier for women than for men (58 vs 61 months; p=0.024).White race (vs black) was also associated with increased risk of GDD exposure (OR 1.693 (95% CI 1.011 to 2.833)) in univariable (p=0.044) and multivariable (p=0.046) analyses. Conclusions: Women are two times more likely to experience GDD exposure than men, independent of age. White race is also a risk factor for exposure.